Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Prescient Therapeutics Limited ( (AU:PTX) ) has shared an announcement.
Prescient Therapeutics Limited announced a change in the director’s interest, with James Campbell acquiring 222,000 fully paid ordinary shares through an on-market trade. This change reflects a significant increase in the director’s stake, indicating confidence in the company’s future prospects and potentially impacting investor perceptions positively.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative cancer treatments. The company specializes in targeted therapies and personalized medicine, aiming to improve patient outcomes in oncology.
YTD Price Performance: -6.00%
Average Trading Volume: 617,193
Technical Sentiment Signal: Hold
Current Market Cap: A$37.85M
For detailed information about PTX stock, go to TipRanks’ Stock Analysis page.